Idarucizumab OverviewIdarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran. Idarucizumab was developed by Boehringer Ingelheim. One study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes. It was approved by the U.S. Food and Drug Administration (FDA) in October 2015. Contents 1 Society and culture 1.1 Names 2 See al...
Read more Idarucizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Idarucizumab
Recent Idarucizumab Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 2.5g/50ml
Other drugs which contain Idarucizumab or a similar ingredient: (1 result)
- PRAXBIND Idarucizumab